Oncomine Myeloid Panel (MDS, MPN, AML, CML, CMML, JMML) – Next-Generation Sequencing in UAE

Executive Summary & Core Metrics

The Oncomine Myeloid Panel is a comprehensive next‑generation sequencing (NGS) assay that interrogates DNA and RNA to detect clinically relevant mutations, fusions, and gene expression profiles across all major myeloid malignancies—MDS, MPN, AML, CML, CMML, and JMML. Processed at our DHA‑licensed laboratory (License 1143) in Dubai Healthcare City, this panel achieves a diagnostic sensitivity of 99.9% under ISO 9001:2015 accreditation.

Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited NGS processing.
Clinical Guidance: Complimentary telephonic post‑test interpretation with a DHA‑licensed consultant geneticist.
Insurance: Direct billing verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

In a single bone marrow or peripheral blood sample, the Oncomine Myeloid Panel replaces multiple single‑gene tests and provides a complete molecular landscape within 14–21 business days. This comprehensive approach empowers precise risk stratification and targeted therapy decisions for patients with suspected or confirmed myeloid neoplasms.

Feature	Our Oncomine Myeloid Panel	Closest Alternative (Conventional Karyotyping & Single‑Gene PCR)
Precision	≥99.9% diagnostic sensitivity for 40+ genes and 29 fusion drivers	~60–70% detection rate; misses cryptic fusions and multiple mutations
Methodology	Next Generation Sequencing (DNA + RNA), ISO 9001:2015	Karyotyping, FISH, single‑gene Sanger sequencing
Turnaround Time	14–21 business days	3–6 weeks (multiple sequential tests)

Physician Insight & Safety Protocols

Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403

“The comprehensive genomic landscape provided by this single NGS panel is fundamental for precise risk stratification in myeloid malignancies. I strongly recommend discussing all revealed variants, including those of uncertain significance, with your hematologist or oncologist to correlate molecular findings with clinical presentation and standard cytogenetic results.”

⚠️ Medication Advisory

Do not modify or discontinue any prescribed therapy, including targeted agents or supportive care, solely on the basis of preliminary molecular findings. Always consult your treating physician for clinical correlation and therapeutic adjustments.

Exclusion Criteria & Emergency Red Flags

Bone marrow aspiration is contraindicated in patients with severe uncorrected coagulopathy or platelet count <20 × 10⁹/L without appropriate supportive measures.
Informed consent is mandatory for all procedures, in compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
Emergency Red Flags: Persistent fever ≥38.5°C, uncontrolled bleeding, or acute dyspnea require immediate medical attention. Do not delay for laboratory scheduling.

Patient FAQ & Clinical Guidance

1. Why is the Oncomine Myeloid Panel recommended over single-gene tests?

This panel interrogates 40+ genes and 29 fusion drivers simultaneously in one NGS workflow, delivering a comprehensive molecular diagnosis within 14–21 business days. It replaces the need for sequential single-gene tests, reducing time to treatment decision.

2. How is the sample collected and what are the logistics?

The preferred sample is a bone marrow aspirate, collected by a qualified hematologist in an accredited hospital setting. A peripheral blood sample (5 mL EDTA) may be accepted for monitoring. Note: Hospital Extraction Only – mobile home phlebotomy is disabled for this invasive procedure.

3. When will I receive my results and how are they interpreted?

Results are typically available within 14–21 business days. A complimentary telephonic consultation with our DHA-licensed genetic consultant is provided to discuss the clinical implications of the report.

UAE Regulatory & Data Privacy Adherence

Data Privacy & Confidentiality: All genomic data and personal health information are processed in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your data is encrypted, access-controlled, and used solely for diagnostic purposes.

Clinical Safety: Sample collection adheres to the standards set forth in Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring patient safety and informed consent protocols are rigorously followed. DNA Labs UAE is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139).

Clinical & Logistical Metadata

Test Name	Oncomine Myeloid Panel (MDS, MPN, AML, CML, CMML, JMML)
Price (AED)	5,000
Turnaround Time	14–21 Business Days
Sample Type / Matrix	Bone Marrow Aspirate (preferred) / Peripheral Blood (5 mL EDTA). Hospital Extraction Only.
Methodology Used	Next Generation Sequencing (NGS) – DNA & RNA, ISO 9001:2015 Accredited
ICD-10-CM Code	C92.90, C93.90, C94.40, D46.9, D47.1
LOINC Code	98557-3
DHA Facility License & Address	License 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE